Fluoroquinolones protect the human lymphocyte CEM cell line from HIV-1-mediated cytotoxicity.

Nozaki-Renard, Junko; Iino, Takashi; Sato, Yasuomi D.; Marumoto, Yasumasa; Ohta, Genkichi; Furusawa, Mitsuru

doi:10.1247/csf.15.295

Cited by 19 publications

(12 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In this report, we compared the activity of R-71762 and other authentic fluoroquinolones that were employed in previous studies [23,24]. The results clearly demonstrate that R-71762 protects MT-4 cells against HIV-1-induced cytopathic effects, but the other compounds do not.…”

Section: Introductionmentioning

confidence: 81%

“…Nozaki-Renard et al [23,24] reported that some fluoroquinolones (ofloxacin, levofloxacin, ciprofloxacin, norfloxacin and enoxacin) protected human lymphocyte cell lines (MT4 and CEM cells) from HIV-1-induced cytopathic effects when cells were treated for a fairly long period. In this study, none of these compounds showed protective activities against HIV-1-induced cytopathic effects in MT-4 cells when the cells were treated for a short period (5 days, fig.…”

Section: Discussionmentioning

confidence: 99%

“…There is great interest in the development of antiviral quinolone with a unique mode of action. NozakiRenard et al [23,24] reported that some antibacterial fluoroquinolones protected human lymphocyte cell lines from HIV-1-induced cytopathicity. Recently, Gollapudi et al [25] reported that ciprofloxacin, an antimicrobial quinolone, inhibited HIV-1 expression in promonocytic U1 cells at least in part by inhibiting the action of NF-ÎB.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

A New Fluoroquinolone Derivative Exhibits Inhibitory Activity against Human Immunodeficiency Virus Type 1 Replication

et al. 1999

View full text Add to dashboard Cite

The inhibitory activity of several fluoroquinolone antibiotics against human immunodeficiency virus type 1 (HIV-1) replication was investigated. R-71762, (±) 9-fluoro-3-fluoromethyl-2,3-dihydro-10-[4-(2-pyridyl)-1-piperazinyl]-7-oxo-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid, protected MT-4 cells from HIV-1-induced cytopathic effects. Furthermore, the compound inhibited virus replication both in acutely and in chronically HIV-1-infected cells. On the other hand, ofloxacin, levofloxacin, ciprofloxacin, norfloxacin and enoxacin, that were previously reported to be protective against HIV-1-induced cytopathic effects, did not show any protective activity in our assay system. These results indicate that R-71762 is a novel inhibitor of HIV-1 replication and is effective even in HIV-1 chronically infected cells.

show abstract

Section: Introductionmentioning

confidence: 81%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A New Fluoroquinolone Derivative Exhibits Inhibitory Activity against Human Immunodeficiency Virus Type 1 Replication

et al. 1999

View full text Add to dashboard Cite

show abstract

“…There is great interest in the development of antiviral quinolones with a unique mode of action. Nozaki-Renard et al reported that some anti-bacterial fluoroquinolones protected human lymphocyte cell lines from HIV-1-induced cytopathicity [25,26]. However, we failed to reproduce their results in our assay system [19].…”

mentioning

confidence: 64%

8-Difluoromethoxy-4-Quinolone Derivatives as Anti-Feline Immunodeficiency Virus (FIV) Agents: Important Structural Features for Inhibitory Activity of FIV Replication

Kashiwase¹,

Katsube

Kimura

et al. 2000

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. The inhibitory activities of various 8-difluoromethoxy-4-quinolone derivatives against feline immunodeficiency virus (FIV) replication in the chronically infected cell line P-CrFK were investigated. Certain derivatives were found to inhibit FIV production from PCrFK cells in a dose-dependent manner without exhibiting cytotoxic effects at inhibitory concentrations. Based on this study, the structures important for anti-FIV activity are suggested to be (i) a carboxyl group at position C-3, and (ii) an aromatic modification at position 4 of the C-7 piperazinyl moiety.-KEY WORDS: antiviral agent, arylpiperazinyl fluoroquinolone, feline immunodeficiency virus (FIV), inhibitor of FIV replication.

show abstract

“…10:S197, 1996). They have also been reported to possess antiviral properties against both DNA and RNA viruses, including HCV (6,10,11). However, their value in HCV has largely been limited to patients with relatively mild, precirrhotic chronic hepatitis (7,12,13).…”

mentioning

confidence: 99%

Use of Fluoroquinolones in Patients with Chronic Hepatitis C Virus-Induced Liver Failure

Kojima

Kaita

Hawkins

et al. 2002

Antimicrob Agents Chemother

View full text Add to dashboard Cite

Fluroquinolone antibiotics have been reported to have antiviral properties against RNA viruses, including hepatitis C virus (HCV). In the present study, five patients with advanced liver disease secondary to chronic HCV received 500 mg daily of oral ciprofloxacin for 30 days. Serum HCV-RNA levels and liver enzyme abnormalities remained largely unchanged. Thus, the role of fluoroquinolones as antiviral agents for chronic HCV in patients with advanced liver disease appears to be limited

show abstract

Fluoroquinolones protect the human lymphocyte CEM cell line from HIV-1-mediated cytotoxicity.

Cited by 19 publications

References 23 publications

A New Fluoroquinolone Derivative Exhibits Inhibitory Activity against Human Immunodeficiency Virus Type 1 Replication

A New Fluoroquinolone Derivative Exhibits Inhibitory Activity against Human Immunodeficiency Virus Type 1 Replication

8-Difluoromethoxy-4-Quinolone Derivatives as Anti-Feline Immunodeficiency Virus (FIV) Agents: Important Structural Features for Inhibitory Activity of FIV Replication

Use of Fluoroquinolones in Patients with Chronic Hepatitis C Virus-Induced Liver Failure

Contact Info

Product

Resources

About